MCID: RBL001
MIFTS: 58

Rubella malady

Categories: Rare diseases, Infectious diseases, Skin diseases, Fetal diseases, Neuronal diseases

Aliases & Classifications for Rubella

About this section

Summaries for Rubella

About this section
MedlinePlus:35 Rubella is an infection caused by a virus. it is usually mild with fever and a rash. about half of the people who get rubella do not have symptoms. if you do get them, symptoms may include a rash that starts on the face and spreads to the body mild fever aching joints, especially in young women swollen glands rubella is most dangerous for a pregnant woman's baby. it can cause miscarriage or birth defects. rubella spreads when an infected person coughs or sneezes. people without symptoms can still spread it. there is no treatment, but the measles-mumps-rubella (mmr) vaccine can prevent it. centers for disease control and prevention

MalaCards based summary: Rubella, also known as german measles, is related to retinitis and dysgammaglobulinemia, and has symptoms including rash on the face which spreads to the trunk, fever and lymphadenopathy. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways are Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics and Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. Affiliated tissues include skin, heart and skin.

Disease Ontology:10 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC:2 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in an developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia:68 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

About this section

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 211)
idRelated DiseaseScoreTop Affiliating Genes
1retinitis30.2HLA-A, HLA-B
2dysgammaglobulinemia30.2CD40LG, IL10
3iridocyclitis30.0HLA-A, HLA-B, HLA-C
4intermediate uveitis30.0HLA-A, HLA-B
5hemolytic anemia29.4HLA-A, HLA-B, HLA-C, IL10
6congenital rubella12.5
7rubella panencephalitis12.1
8measles11.2
9mumps11.1
10acute poststreptococcal glomerulonephritis10.6CD40LG, HLA-B
11metanephric adenoma10.6HLA-B, MOG
12oropouche fever10.6CD40LG, IL10
13malignant hypertensive renal disease10.6CD40LG, MOG
14causalgia10.6HLA-DPB1, MOG
15louping ill10.5CD40LG, IL10
16periventricular leukomalacia10.5HLA-A, HLA-B
17postinfectious encephalomyelitis10.5HLA-A, HLA-B
18hydromyelia10.5HLA-A, HLA-B
19portal hypertension10.5CD40LG, HLA-A
20acute disseminated encephalomyelitis10.5
21anthracosis10.4HLA-A, HLA-B
22undetermined early-onset epileptic encephalopathy10.4HLA-A, HLA-B
23prostate malignant phyllodes tumor10.4HLA-A, HLA-B
24drug-induced mental disorder10.4HLA-C, IL10
25acquired thrombocytopenia10.4HLA-A, HLA-B
26hypercementosis10.4HLA-B, IL10
27estrogen excess10.4HLA-A, HLA-B
28b cell deficiency10.4CD40LG, IL10
29hemorrhagic proctocolitis10.4CD40LG, IL10
30malignant hypertension10.4HLA-A, HLA-B
31large intestine lipoma10.4CD40LG, IL10, MOG
32noonan-like/multiple giant cell lesion syndrome10.4HLA-A, HLA-B
33lymphocytic choriomeningitis10.4HLA-A, HLA-B
34mental retardation, autosomal dominant 710.3IL10, IL10RB
35aniseikonia10.3CD40LG, IL10
36jejunal somatostatinoma10.3CD40LG, IL10, MOG
37upper lip cancer10.3CD40LG, IL10, MOG
38bk-virus nephropathy10.3HLA-A, HLA-C
39inflammatory spondylopathy10.3HLA-A, HLA-B, MOG
40human granulocytic anaplasmosis10.3CD40LG, DDX58
41cll/sll10.3CD40LG, HLA-B, IL10
42limited scleroderma10.2CD40LG, HLA-B, IL10
43cerebellar angioblastoma10.2CD40LG, HLA-DPB1, IL10
44monocular exotropia10.2CD40LG, HLA-A, HLA-B
45subcorneal pustular dermatosis10.2HLA-A, HLA-B, HLA-DPB1
46cryptosporidiosis10.2HLA-A, HLA-B
47hepatitis10.2
48juvenile pilocytic astrocytoma10.2HLA-A, HLA-B
49psoriasis10.2HLA-A, HLA-B, HLA-C
50acneiform dermatitis10.2HLA-A, HLA-B, HLA-C

Graphical network of the top 20 diseases related to Rubella:



Diseases related to rubella

Symptoms for Rubella

About this section

Symptoms:

 10
  • rash on the face which spreads to the trunk
  • fever
  • lymphadenopathy
  • joint pains
  • headache
  • conjunctivitis

UMLS symptoms related to Rubella:


rubella arthralgia, pruritus, exanthema

Drugs & Therapeutics for Rubella

About this section

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1ImmunoglobulinsPhase 4, Phase 1, Phase 24477
2Heptavalent Pneumococcal Conjugate VaccinePhase 4, Phase 3, Phase 2440
3AntibodiesPhase 4, Phase 1, Phase 24477
4Pharmaceutical SolutionsPhase 4, Phase 3, Phase 27004
5VaccinesPhase 4, Phase 3, Phase 2, Phase 1, Phase 06085
6Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
7Liver ExtractsPhase 43572
8
Aluminum hydroxideapprovedPhase 3, Phase 2178
Synonyms:
Al(OH)3
Aluminiumhydroxid
 
Aluminum Hydroxide
Aluminum hydroxide
Dermadrox
9
Vitamin Aapproved, nutraceuticalPhase 341311103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(2e,4e,6e,8e)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Chocola a
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A palmitate
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin a
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
10PENTAPhase 3, Phase 2109
11
LactitolPhase 3, Phase 2320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
12Trace ElementsPhase 33900
13VitaminsPhase 33857
14Retinol palmitatePhase 3413
15AntioxidantsPhase 32442
16MicronutrientsPhase 33901
17Protective AgentsPhase 35651
18retinolNutraceuticalPhase 3413
19
AltretamineapprovedPhase 257645-05-62123
Synonyms:
2,4, 6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylami
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
2,4,6-Tris(dimethylamino)-s-triazine
2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
549835_ALDRICH
645-05-6
A 8723
A0567/0026158
A8723_SIGMA
AB00052308
AC-12006
AC1L1CYX
AI3-50852
AKOS001729401
Altretamin
Altretamina
Altretamina [INN-Spanish]
Altretamine (USP/INN)
Altretamine Bellon Brand
Altretamine Chiesi Brand
Altretamine Wassermann Brand
Altretamine [USAN:INN:BAN]
Altretaminum
Altretaminum [INN-Latin]
Altrétamine
BPBio1_001004
BRD-K67043667-001-04-1
BRN 0195058
BSPBio_000912
Bellon Brand of Altretamine
C9H18N6
CAS-654-05-6
CCRIS 5492
CHEBI:24564
CHEMBL1455
CID2123
CPD000058181
ChemDiv2_005185
Chiesi Brand of Altretamine
D006585
D02841
DB00488
DivK1c_000772
EINECS 211-428-4
ENT 50852
EU-0100083
FT-0083576
HEXAMETHYLMELAMINE
HMM
HMS1383L15
HMS1570N14
HMS1922C05
HMS2090G17
HMS2092H16
HMS502G14
HSDB 7559
HTM
HXM
Hemel
Hexalen
Hexalen (TN)
Hexalen, Altretamine
 
Hexamethylmelamine
Hexastat
Hexinawas
I06-0604
IDI1_000772
IDI1_003900
InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H
KB-913
KBio1_000772
KBio2_001788
KBio2_004356
KBio2_006924
KBio3_002042
KBioGR_001388
KBioSS_001788
LS-1549
Lopac-A-8723
Lopac0_000083
MGI Pharma Brand of Altretamine
MLS000069621
MLS001076123
MolPort-002-111-210
N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine
NC 195
NCGC00015100-01
NCGC00015100-02
NCGC00015100-03
NCGC00015100-06
NCGC00015100-11
NCGC00021216-03
NCGC00021216-04
NCGC00021216-05
NCGC00021216-06
NCGC00021216-07
NCI-C50259
NCI60_000871
NINDS_000772
NSC 13875
NSC-13875
NSC13875
N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine
Prestwick0_000946
Prestwick1_000946
Prestwick2_000946
Prestwick3_000946
Rhone Poulenc Rorer Brand of Altretamine
Rhone-Poulenc Rorer Brand of Altretamine
S1278_Selleck
SAM002564241
SMR000058181
SPBio_000754
SPBio_003071
SPECTRUM1503065
ST086739
STK749184
Spectrum2_000907
Spectrum3_000951
Spectrum4_001064
Spectrum5_001092
Spectrum_001308
UNII-Q8BIH59O7H
WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1
Wassermann Brand of Altretamine
ZINC00000905
altretamine
no)-s-triazine
20Immunoglobulin GPhase 1146
21Immunoglobulin MPhase 19
22AutoantibodiesPhase 1117
23
Azathioprineapproved153446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
 
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
24
Adalimumabapproved443331731-18-116219006
Synonyms:
331731-18-1
Adalimumab
Adalimumab (USAN/INN)
Adalimumab (genetical recombination)
 
Adalimumab (genetical recombination) (JAN)
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
25
Infliximabapproved349170277-31-3
Synonyms:
Ig gamma-1 chain C region
 
Inflectra
Remicade
Remsima
26
Methotrexateapproved14441959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
27
Certolizumab pegolapproved117428863-50-7
Synonyms:
428863-50-7
CDP870
Certolizumab pegol
 
Certolizumab pegol (USAN/INN)
Certolizumab pegol (genetical recombination)
Certolizumab pegol (genetical recombination) (JAN)
Cimzia
D03441
28Adjuvants, Immunologic1783
296-Mercaptopurine185
30AcidophilusNutraceutical482

Interventional clinical trials:

(show top 50)    (show all 119)
idNameStatusNCT IDPhase
1Coadministration of Measles-rubella and Rotavirus VaccinesCompletedNCT01700621Phase 4
2Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00126997Phase 4
3Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic ArthritisCompletedNCT00731965Phase 4
4Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined VaccineCompletedNCT00313950Phase 4
5Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT00962819Phase 4
6MMR Vaccination Among HIV-infected AdultsCompletedNCT02724852Phase 4
7Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.CompletedNCT00388440Phase 4
8Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)CompletedNCT00312858Phase 4
9Safety Study of a Refrigerator-Stable Formulation of VARIVAX®CompletedNCT00432731Phase 4
10MMR and Varicella Vaccine in Premature InfantsCompletedNCT00156559Phase 4
11IPV Clinical Trial - The GambiaCompletedNCT01847872Phase 4
12Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old ChildrenCompletedNCT02253407Phase 4
13Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIVCompletedNCT00329251Phase 4
14Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesRecruitingNCT02643433Phase 4
15Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRRecruitingNCT02325310Phase 4
16Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsRecruitingNCT01777529Phase 4
17Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 4
18The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR VaccineEnrolling by invitationNCT02153866Phase 4
19Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesTerminatedNCT00138255Phase 4
20Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3
21Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127023Phase 3
22Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3
23Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 3
24Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 3
25Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127010Phase 3
26Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 3
27Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 3
28Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 3
29Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 3
30Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3
31Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
32ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3
33Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 3
34Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3
35A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3
36Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety StudyCompletedNCT00326183Phase 3
37Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in ChildrenCompletedNCT00197015Phase 3
38Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined VaccineCompletedNCT00406211Phase 3
39Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered ConcomitantlyCompletedNCT00432042Phase 3
40Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3
41ProQuad® rHA SafetyCompletedNCT00560755Phase 3
42Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxCompletedNCT00226499Phase 3
43Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy ChildrenCompletedNCT00192491Phase 3
44Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedNCT00984295Phase 3
45Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 3
46Comparative Study of Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHACompletedNCT00566527Phase 3
47V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3
48ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3
49A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3
50Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3

Search NIH Clinical Center for Rubella


Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

About this section

Anatomical Context for Rubella

About this section

MalaCards organs/tissues related to Rubella:

33
Heart, Skin, Brain, Eye, Testes, Breast, Prostate

FMA organs/tissues related to Rubella:

16
Skin

Animal Models for Rubella or affiliated genes

About this section

MGI Mouse Phenotypes related to Rubella:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes

Publications for Rubella

About this section

Articles related to Rubella:

(show top 50)    (show all 1193)
idTitleAuthorsYear
1
Rubella immunity among pregnant women aged 15-44 years, Namibia, 2010. (27196370)
2016
2
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9a88months of age: a phase III, randomised, non-inferiority trial. (26362659)
2015
3
Epidemiologic Surveillance on Measles, Rubella and Congenital Rubella Syndrome. Spain]. (26580792)
2015
4
Seroprevalence of measles, mumps and rubella among young adults, after 20A years of universal two-dose MMR vaccination in Israel. (25891446)
2015
5
Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. (25734162)
2014
6
Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella. (24412300)
2014
7
Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. (23246259)
2013
8
Influence of Vaccination dose and clinico-demographical factors on antibody titers against measles, rubella, mumps, and varicella-zoster viruses among university students in Japan. (24270137)
2013
9
Magnetic resonance imaging findings in a case of congenital rubella encephalitis. (24489572)
2013
10
Rubella in Poland in 2011. (24040714)
2013
11
The importance of fundus eye testing in rubella-induced deafness. (23911114)
2013
12
Congenital rubella syndrome: a review of laboratory data from 2002 to 2011. (24050074)
2013
13
Congenital rubella syndrome and left pulmonary artery sling. (22298614)
2012
14
An outbreak of rubella in the Federation of Bosnia and Herzegovina between December 2009 and May 2010 indicates failure to vaccinate during wartime (1992-1995). (21524344)
2012
15
Letter to the editor: commitment needed for the prevention of congenital rubella syndrome in Europe. (22433598)
2012
16
Rubella vaccines: WHO position paper--recommendations. (21930175)
2011
17
Development of microsatellite markers in Capsella rubella and Capsella bursa-pastoris (Brassicaceae). (21700797)
2011
18
Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination--United States, 2001-2010. (21592401)
2011
19
Application of new assays for rapid confirmation and genotyping of isolates of rubella virus. (21108356)
2011
20
Unusual nucleotide content of Rubella virus genome as a consequence of biased RNA-editing: comparison with Alphaviruses. (21441098)
2011
21
Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. (20001730)
2010
22
Surveillance and control of rubella in the republic of Korea from 2001 to 2009: the necessity for enhanced surveillance to monitor congenital rubella syndrome. (24159436)
2010
23
Development of a novel TaqMan real-time PCR assay for detecting rubella virus RNA. (20580632)
2010
24
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. (20587679)
2010
25
Could the United States experience rubella outbreaks as a result of vaccine refusal and disease importation? (21150305)
2010
26
Closer look at autism and the measles-mumps-rubella vaccine. (21071320)
2010
27
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. (19576941)
2009
28
Chlamydia trachomatis and rubella antibodies in women with full-term deliveries and women with abortion in Baghdad. (20218131)
2009
29
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. (19007835)
2009
30
Development of the rubella vaccine and vaccination strategy in Japan. (19366581)
2009
31
Humoral immune response to primary rubella virus infection. (16522781)
2006
32
Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. (15655774)
2005
33
Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. (15717298)
2005
34
The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. (12435771)
2002
35
Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. (10390298)
1999
36
Use of PCR for prenatal and postnatal diagnosis of congenital rubella. (8576339)
1995
37
Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays. (1572968)
1992
38
Rubella surveillance to december 1990: a joint report from the PHLS and National Congenital Rubella Surveillance Programme. (1669769)
1991
39
Development of a highly specific and sensitive rubella immunoglobulin M antibody capture enzyme immunoassay that uses enzyme-labeled antigen. (2185260)
1990
40
Congenital rubella syndrome in Malaysia. (3831727)
1985
41
Birth and death of congenital rubella syndrome. (6700106)
1984
42
The HLA system in congenital rubella patients with and without diabetes. (6959935)
1982
43
Congenital rubella syndrome: a continuing problem. (6799666)
1982
44
Congenital rubella, insulitis, and diabetes mellitus in an infant. (6112424)
1981
45
Keratoconus and acute hydrops in mentally retarded patients with congenital rubella syndrome. (7468739)
1981
46
Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. (386238)
1979
47
The devastating effects of congenital rubella. (106205)
1979
48
Nuclear and cytoplasmic immunofluorescence in the cerebrospinal fluid cells from a neonate with congenital rubella. (347227)
1977
49
Congenital rubella--an encapsulated review. (960007)
1976
50

Variations for Rubella

About this section

Expression for genes affiliated with Rubella

About this section
Search GEO for disease gene expression data for Rubella.

Pathways for genes affiliated with Rubella

About this section

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show top 17)    (show all 18)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.2DDX58, IL10RB
29.0CD40LG, HLA-A, HLA-B, HLA-C
39.0CALR, HLA-A, HLA-B, HLA-C
48.9IFNA21, IL10, IL10RB
5
Show member pathways
8.9CD40LG, HLA-A, HLA-C, HLA-DPB1
6
Show member pathways
8.8CD40LG, HLA-DPB1, IL10, IL10RB
7
Show member pathways
8.6HLA-A, HLA-B, HLA-C, IFNA21
88.6CD40LG, HLA-A, HLA-B, HLA-C, HLA-DPB1
98.5CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1
108.5CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1
118.5HLA-DPB1, IFNA21, IL10, IL10RB
12
Show member pathways
8.1HLA-A, HLA-B, HLA-C, IFNA21, IL10
13
Show member pathways
7.1C1QBP, DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1
147.0DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1, IL10
15
Show member pathways
6.7CALR, CD40LG, HLA-A, HLA-B, HLA-C, HLA-DPB1
16
Show member pathways
6.7DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1, IFNA21
17
Show member pathways
5.8CALR, CD40LG, DDX58, HLA-A, HLA-B, HLA-C

GO Terms for genes affiliated with Rubella

About this section

Cellular components related to Rubella according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.9HLA-C, HLA-DPB1
2ER to Golgi transport vesicle membraneGO:00125079.1HLA-A, HLA-C, HLA-DPB1
3cell surfaceGO:00099869.0CALR, HLA-A, HLA-B, HLA-C

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of substrate adhesion-dependent cell spreadingGO:190002610.5C1QBP, CALR
2protection from natural killer cell mediated cytotoxicityGO:004227010.4HLA-A, HLA-B
3positive regulation of T cell mediated cytotoxicityGO:000191610.4HLA-A, HLA-B
4negative regulation of interleukin-12 productionGO:003269510.2C1QBP, IL10
5B cell proliferationGO:00421009.9IFNA21, IL10
6positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.7IL10, TRIM22, TRIM5
7B cell differentiationGO:00301839.6CD40LG, IFNA21, IL10
8antigen processing and presentation of peptide antigen via MHC class IGO:00024749.6HLA-A, HLA-B, HLA-C
9antigen processing and presentationGO:00198829.3HLA-A, HLA-B, HLA-C, HLA-DPB1
10cytokine-mediated signaling pathwayGO:00192219.2HLA-DPB1, IFNA21, TRIM22, TRIM5
11defense response to virusGO:00516079.1IFNA21, IL10RB, TRIM22
12interferon-gamma-mediated signaling pathwayGO:00603338.9HLA-A, HLA-B, HLA-C, TRIM22, TRIM5
13immune responseGO:00069558.7C1QBP, IL10, IL10RB, TRIM22
14viral processGO:00160328.4C1QBP, HLA-A, HLA-B, HLA-C, TRIM22, TRIM5

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptide antigen bindingGO:00426059.8HLA-A, HLA-B

Sources for Rubella

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet